Led · Seed · Jun 2026

Seagate Space develops Gateway-S, a semi‑submersible, dynamically positioned (DP-2) offshore launch platform with a modular architecture intended to support different small-to-medium launch vehicles. The platform is designed for rockets up to 24 meters in length and aims to enable higher cadence offshore launches, with the company targeting first missions in 2027. Since its January 2025 founding in St. Petersburg, Florida, Seagate Space has signed MOUs with Firefly Aerospace, Oceaneering International, and Lockheed Martin to distribute engineering responsibilities and mission concepts. The company conducted hydrodynamic scale-model tests at MIT Sea Grant Hydrodynamics Laboratory and in December 2025 received an Approval in Principle from the American Bureau of Shipping under new standards for offshore spaceports. Financially, Seagate closed an oversubscribed $1.5M pre-seed round with New World Angels and DraperU Ventures and announced an additional, undisclosed strategic investment from Space Florida. The firm has not disclosed full project budgets or a valuation.

Participated · Series A · Aug 2024

Prana Thoracic develops the Prana System, an image-guided, minimally invasive platform designed to enable precision surgical solutions that conserve healthy tissue and support personalized treatment plans for lung cancer. The company targets earlier interventions for patients and says the system can be applied across a range of conditions including lung cancer. Prana is also exploring use of the technology in other soft tissues and investigating integration with ablation and robotic systems. Its team includes surgeons, engineers, and entrepreneurs and is led by CEO and co-founder Joanna Nathan. Financially, the company has raised $9 million to date—an initial $3M, a $3M non-dilutive grant, and a $3M Series A extension that was oversubscribed by 30%. The new funding will be used to accelerate product development and advance clinical and regulatory plans. Prana Thoracic is developing the ThoraCore System, a minimally invasive, lung-sparing tool designed to target hard-to-reach pulmonary nodules and enable definitive diagnosis earlier in the lung cancer care pathway. The company’s technology was developed on the Texas Medical Center campus in collaboration with Precision Thoracic Corporation and inventor Edward M. Boyle, MD. Prana is led by CEO and co-founder Joanna Nathan. The company announced the closing of a $3.0 million founding Series A financing and previously received a $3.0 million award from the Cancer Prevention & Research Institute of Texas. Proceeds from the Series A and the CPRIT award will be used for product development and to support first-in-human clinical studies. Prana positions the ThoraCore System to improve diagnostic access for patients with challenging lung nodules and accelerate earlier intervention. Prana Thoracic is developing a minimally invasive, tissue-sparing lung tissue excision tool intended to provide definitive diagnosis of suspicious pulmonary nodules earlier in the patient journey. The company says the device targets nodules that are challenging to sample, filling a gap between needle biopsy and open chest procedures. Prana Thoracic aims to commercialize the technology through first-in-human studies supported by the award. The company notes that lung cancer is the leading cause of cancer death in the U.S. and that screening rates are low despite large eligible populations. Prana Thoracic partnered with the Johnson & Johnson MedTech Center for Device Innovation for design and early testing. Joanna Nathan is CEO and founder, and Dr. Edward Boyle is a founder and one of the inventors of the technology.

Led · Convertible Note · Jan 2024

Fuego produces patented dance sneakers engineered for dancing and spinning on any surface and worn by dancers in 120 countries. The company sells tech-enabled, dance-inspired athleisure and lifestyle products across formats including hip-hop, ballroom, salsa, dance fitness, swing, ballet and jazz. Fuego has collaborated on product drops such as the Jade x Fuego low-top made with recycled plastic water bottles. Led by CEO Kevin Weschler, the company is focusing on new product development and global expansion. The recent financing will provide capital to continue product development and support international growth. An investor from the round, New World Angels, will have a representative join Fuego’s board as an observer.

Participated · Series D · Jul 2022

Clarke Valve provides industrial control valves for organizations worldwide, with technology deployed across oil and gas, chemical, power plants, water management, and aerospace markets. Founded in 2011 and led by CEO Kyle Daniels, the company is based in North Kingstown, Rhode Island. On July 27, 2022, Clarke Valve closed a $5 million Series D funding round led by Flowserve Corporation. Participants in the round included OGCI Climate Investments, Saudi Aramco Energy Ventures, Chevron Technology Ventures and New World Angels. The company intends to use the funds to continue to expand operations and its business reach. Clarke Valve designs and manufactures the patented Shutter Valve, a full-bore control valve engineered to virtually eliminate fugitive emissions while delivering high flow rate, zero pressure drop, zero leakage, and reduced cavitation and pitting. The company says its Shutter Valves are typically one-fifth the weight, size, and cost of equivalent legacy valves and are currently the only control valves to achieve API 641 certification for low fugitive emission performance. Clarke assembles its standard products at its headquarters in North Kingstown, Rhode Island. The company plans to roll out its proprietary solution globally, offer retrofit options for the majority of competitive valves in the marketplace, and capture market share to reduce methane emissions from legacy valve designs. Financially, Clarke completed a $5.5 million sale of Series B Preferred Stock in this round, bringing Series B funding to $15.5 million and total investor capital raised to over $23 million. Clarke Industrial Engineering develops and commercializes a proprietary Shutter Valve designed to change control valve technology. The company targets the $84 billion worldwide industrial valve market, with applications in oil and gas and beyond. Its core product aims to provide a step change in performance compared with traditional control valves. Clarke highlights strategic industry validation from major purchasers that have invested in the company. The firm completed a $10 million Series B financing to institutional and corporate investors. Clarke is headquartered in North Kingstown, Rhode Island. Clarke Industrial Engineering markets and produces the patented Shutter Valve, introduced in 2014 and invented by founder and CEO Kyle Daniels. The Shutter Valve is presented as a major innovation in the valve industry, offering precision flow control, zero pressure drop and zero leakage versus traditional gate, ball and butterfly valves. Clarke reports blue‑chip customers across natural gas, water, power, paper and chemical industries and has a licensing arrangement with Curtiss‑Wright to enter defense and nuclear markets. The company maintains sales, marketing and finance operations in Miami and engineering and production operations in Rhode Island. The business is using external capital to scale production and expand its product line and performance specifications across industries. Clarke Industrial Engineering develops and sells the patented Shutter Valve, including 1', 2' and 4' sizes. The company says its valve combines aerospace-inspired design for high flow-control performance with ease of manufacturing. Recent hires and leadership additions aim to scale volume production and supply-chain management. Management changes include the addition of Jeff Buck (engineering and production executive) and Chad Heffernan as Manager of Sales & Marketing. Clarke states its lead customers represent billions of dollars of industrial revenue and that volume builds will yield cost efficiencies and competitive pricing. The company is based in N. Kingstown, RI and positions itself to target the global $100 billion valve market.

Led · Series A · Jan 2022

Vesteck is an early-stage medical device company based in West Chester, Pa., led by CEO Joe Rafferty and CMO Dr. David H. Deaton. The company has designed a platform comprised of six devices that integrate delivery of nitinol sutures into a catheter to improve clinical outcomes for endovascular aortic aneurysm patients. Its first product, the “Suture-Tight” nitinol suture delivery catheter, targets the endovascular aortic repair market. Vesteck intends to serve the aortic repair, structural heart, and GI markets with its proprietary technology. The company plans to use newly raised funds to support manufacturing, pre-clinical testing, and completion of in-human procedures. These steps are intended to precede a clinical study aimed at FDA clearance.